krn-7000 and Hepatitis-C--Chronic

krn-7000 has been researched along with Hepatitis-C--Chronic* in 2 studies

Reviews

1 review(s) available for krn-7000 and Hepatitis-C--Chronic

ArticleYear
Clinical experience with α-galactosylceramide (KRN7000) in patients with advanced cancer and chronic hepatitis B/C infection.
    Clinical immunology (Orlando, Fla.), 2011, Volume: 140, Issue:2

    For over a century, research has sought ways to boost the immune system in order to eradicate tumors and viruses that exist after escaping immunosurveillance. For the treatment of cancer and hepatitis immunotherapeutic strategies have overall had limited clinical success. An urgent need exists therefore to introduce more effective therapeutic approaches. Invariant (i)NKT cells constitute a conserved T lymphocyte lineage with dominant immunoregulatory, antitumor and antiviral effector cell properties. iNKT specifically recognize the glycolipid α-galactosylceramide in the context of CD1d resulting in their activation. Activated iNKT can promote the development of a long-lasting Th1 biased proinflammatory immune response as demonstrated in multiple tumor-metastasis and viral infection models. Here, we will provide a brief overview of the preclinical data of α-galactosylceramide that formed the basis for subsequent clinical trials in patients with advanced cancer and chronic hepatitis B/C, and elaborate on our own clinical experience with α-galactosylceramide in these patient groups.

    Topics: Antigens, CD1d; Antineoplastic Agents; Clinical Trials as Topic; Galactosylceramides; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Killer Cells, Natural; Lymphocyte Activation; Neoplasms

2011

Trials

1 trial(s) available for krn-7000 and Hepatitis-C--Chronic

ArticleYear
Randomized placebo controlled phase I/II trial of alpha-galactosylceramide for the treatment of chronic hepatitis C.
    Journal of hepatology, 2007, Volume: 47, Issue:3

    The glycosphingolipid alpha-galactosylceramide has been shown to activate invariant natural killer T cells when presented in the context of CD1d and induces powerful antiviral immune responses via the production of inflammatory cytokines. The aim of this study was to investigate the safety and the antiviral activity of alpha-galactosylceramide as a novel class of treatment for chronic hepatitis C patients.. International multicenter dose-escalating randomized placebo-controlled phase I/II trial.. Forty patients were allocated to a dose of 0.1 microg/kg (n=9), 1 microg/kg (n=9), 10 microg/kg (n=11) or to placebo (n=11). alpha-Galactosylceramide was well tolerated and no patients were withdrawn due to side effects. Although most patients showed a decrease in invariant natural killer T cells after administration, no clinically relevant suppression of viral replication was observed. Only one patient, a previous non-responder to peginterferon and ribavirin with high baseline invariant natural killer T cell levels, showed profound signs of immune activation, accompanied by a transient 1.3 log decrease in HCV-RNA and a concomitant increase in ALT after the first administration.. alpha-Galactosylceramide used as monotherapy for interferon-refractory patients in doses of 0.1-10 microg/kg is safe and it exerts moderate immunomodulatory effects. However, in its current form it has no significant effect on HCV-RNA levels.

    Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Blood Cells; Cytokines; Dose-Response Relationship, Drug; Female; Galactosylceramides; Hepacivirus; Hepatitis C, Chronic; Humans; Immune System; Killer Cells, Natural; Male; Middle Aged; RNA, Viral; T-Lymphocytes; Treatment Outcome; Virus Replication

2007